These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 16751018)

  • 1. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
    Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
    J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma.
    Hanf G; Brachmann I; Kleine-Tebbe J; Seybold J; Kunkel G; Suttorp N; Noga O
    Allergy; 2006 Sep; 61(9):1141-4. PubMed ID: 16918520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders.
    Heinisch IV; Bizer C; Volgger W; Simon HU
    J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells.
    Roth M; Tamm M
    Ann Allergy Asthma Immunol; 2010 Feb; 104(2):152-60. PubMed ID: 20306819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment.
    van Rensen EL; Evertse CE; van Schadewijk WA; van Wijngaarden S; Ayre G; Mauad T; Hiemstra PS; Sterk PJ; Rabe KF
    Allergy; 2009 Jan; 64(1):72-80. PubMed ID: 19076931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells and eosinophils in bronchial smooth muscle cell death in asthma.
    Solarewicz-Madejek K; Basinski TM; Crameri R; Akdis M; Akkaya A; Blaser K; Rabe KF; Akdis CA; Jutel M
    Clin Exp Allergy; 2009 Jun; 39(6):845-55. PubMed ID: 19400895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between peripheral blood T-cell profiles and airway inflammation in atopic asthma.
    Shirai T; Inui N; Suda T; Chida K
    J Allergy Clin Immunol; 2006 Sep; 118(3):622-6. PubMed ID: 16950280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pretreatment specific IgE and the response to omalizumab therapy.
    Wahn U; Martin C; Freeman P; Blogg M; Jimenez P
    Allergy; 2009 Dec; 64(12):1780-7. PubMed ID: 19627273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.
    Busse WW; Katial R; Gossage D; Sari S; Wang B; Kolbeck R; Coyle AJ; Koike M; Spitalny GL; Kiener PA; Geba GP; Molfino NA
    J Allergy Clin Immunol; 2010 Jun; 125(6):1237-1244.e2. PubMed ID: 20513521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
    Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
    J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher levels of soluble Fas ligand and transforming growth factor-β after omalizumab treatment: a case report.
    Kao SL; Yu HR; Kuo HC; Tsui KY; Wu CC; Chang LS; Liang CD; Chung YH; Yang KD
    J Microbiol Immunol Infect; 2012 Feb; 45(1):69-71. PubMed ID: 22244736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.